Cerdulatinib (hydrochloride)

Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies[1][2].

Product Specifications

CAS Number

[1369761-01-2]

Product Name Alternative

PRT062070 (hydrochloride) ; PRT2070 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

JAK; Syk

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cerdulatinib-hydrochloride.html

Purity

98.96

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(N(CC1)CCN1C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2)(CC)=O.Cl

Molecular Formula

C20H28ClN7O3S

Molecular Weight

482.00

Precautions

H302, H315, H319, H335

References & Citations

[1]Coffey G, et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther. 2014 Dec; 351 (3) : 538-48.|[2]Ishikawa C, et, al. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor. Int J Oncol. 2018 Oct; 53 (4) : 1681-1690.